India's Sun Pharma senior executives swap leadership roles

Chutes and Ladders

Mumbai-based Sun Pharmaceutical Industries has named Kal Sundaram CEO for India and emerging markets for the country's top drugmaker, while Abhay Gandhi was named head of the company's North American division, the Indian Express newspaper reported.

The new roles are an indirect swap of responsibilities, with Sundaram coming back from the U.S. at the start of next year from his job as head of Taro Pharmaceutical Industries, which Sun bought in 2010 from its Israel-based founders. Gandhi previously held the post of CEO of Sun's India and subcontinent business.

Sun founder and Managing Director Dilip Shanghvi remains in control of the firm. Last year, he embarked on a major consolidation effort following the purchase of Ranbaxy Laboratories that included fresh looks at manufacturing operations hit by quality and data issues highlighted by the U.S. FDA

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

In earnings for the year ended March 31, released in May, Sun--the world's fifth largest generics maker--said it was confident a massive reorganization to consolidate operations after its purchase of Ranbaxy Laboratories in 2014 were "on track."  In particular, the company lauded progress in the U.S. market.

- here's the story from the Indian Express

Related Articles:
India's Sun brings home Taro CEO as business plan accelerates

Read more on

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.